First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.
Year: 2010
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: S. K. Sandhu, R. M. Wenham, G. Wilding, M. McFadden, L. Sun, C. Toniatti, M. Stroh, C. L. Carpenter, J. S. De Bono, W. R. Schelman
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4249199995